[1] Kay, S.R.;Fiszbein, A.;Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull.1987 ,
[2] Allsopp, K.; Read, J;Corcoran, R.; Kinderman, P.Heterogeneity in psychiatric diagnostic classification . Psychiatry Res.2019
[3] Escobar, J.I. An insider’s view of the new diagnostic and statistical manual of North American psychiatry (DSM-5). Colmb.Medica 2013
[4] Markowitz, J.C.; Milrod, B.L. Lost in Translation: The value of Psychatric Clinical Trials. J . Clin. Psychiatry 2022
[5] Shad, M.U.High-Dose Therapy in Treatment-RefractoryPsychosis: A Retrospective Study. Prim. Care Companion CNS Disord.2022
[6] Shad, M.U.; Felzien, E.; Roy, K.; Sethi, S. How to identify and manage non- response to clozapine? Asian J. Psychiatr.2019
[7] Grabowski, B. “P<0.05” Might Not Mean What You Think: American Statistical Association Clarifies P Values. JNCI J.Natl.Cancer Inst. 2016 djw194
[8] Citrome, L. Number needed to treat: What it is and what it isn’t,and every clinician should know how to calculate it. J. Clin Psychiatry 2011
[9] Andrade,C.The numbers to treat and harm(NNT, NNH) statistic: What they tell us and what they do not.J.Clin.Psychiatry 2015
[10] Kasper, S.; Dold, M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 2015
[11] Evans,K.; Colloca, L.; Pecina, M.;Katz,N. What can be done to control the placebo response in clinical trials? A narrative review. Contemp. Clin. Trials 2021
[12] Gardner, D.M.;Baldessarini, R.J.;Waraich antipsychotic drugs: A critical overview. Cmaj 2005
[13] Preskorn, S.H.The evolution of antipsychotic drug therapy :Reserpine, chlorpromazineand haloperidol. J . Psychiatr . Pract.2007,
[14] Vardar , M.K.; Ceylan, M.E.; Unsalver, B.O . Assesment of Risk Factors for Tardive Dyskineasia. Psychopharmacol. Bull. 2020
[15] Sarkar, S.; Gupta, N. Drug information update. Atypical antipsychotics and neuroleptic malignent syndrome : Nuances and pragmatics of the association.BJPsych Bull. 2017,
[16] Chew ,M.L.;Mulsant, B.H.; Pollock, B.G.;Lehman,M.E.;Greenspan,A.; Kirshner, M.A.;Bies,R.R.;Kapur, S.; Gharabawi,G.A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 2006
[17] 17. Jeste, D.V.; Blazer, D.; Casey, D.; Meeks, T.; Salzman, C.; Schneider, L.; Tariot, P.; Yaffe, K. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008, 33, 957-970.
[18] Burch, E.A., Jr.; Goldschmidt, T.J. Loxapine in the treatment of psychotic- depressive disorders: Measurement of antidepressant metabolites. South. Med. J. 1983, 76, 991-995.
[19] Waugaman, R.M. Potential lower efficacy of molindone among first-generation antipsychotics. Am. J. Psychiatry 2009, 166, 491.
[20] Pringsheim, T.; Marras, C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst. Rev. 2009, 2009, CD006996.
[21] Kane, J.M.; Leucht, S.; Carpenter, D.; Docherty, J.P. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic D. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J. Clin. Psychiatry 2003, 64 (Suppl. 12), 5–19.
[22] Arnt, J.; Skarsfeldt, T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsy-
[23] chopharmacology 1998, 18, 63-101.
[24] Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P.; Wong, D.T.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14, 87-96.
[25] Seeger, T.F.; Seymour, P.A.; Schmidt, A.W.; Zorn, S.H.; Schulz, D.W.; Lebel, L.A.; McLean, S.; Guanowsky, V.; Howard, H.R.; Lowe, J.A. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 1995, 275, 101-113.
[26] Schotte, A.; Janssen, P.F.M.; Gommeren, W.; Luyten, W.H.M.L.; Van Gompel, P.; Lesage, A.S.; De Loore, K.; Leysen, J.E. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996, 124, 57-73.
[27] Maeda, K.; Lerdrup, L.; Sugino, H.; Akazawa, H.; Amada, N.; McQuade, R.D.; Stensbøl, T.B.; Bundgaard, C.; Arnt, J.; Kikuchi, T. Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin- dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350, 605-614.
[28] Herman, A.; El Mansari, M.; Adham, N.; Kiss, B.; Farkas, B.; Blier, P. Involvement of 5-HT(1A) and 5- HT(2A) Receptors but Not alpha (2)-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo. Mol. Pharmacol. 2018, 94, 1363-1370.
[29] Citrome, L. Iloperidone: Chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability,
[30] regulatory affairs, and an opinion. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1551–1564.
[31] Citrome, L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs 2013, 27, 879–911.
[32] Corena-McLeod, M. Comparative Pharmacology of Risperidone and Paliperidone. Drugs R D 2015, 15, 163–174.
[33] Wenthur, C.J.; Lindsley, C.W. Classics in chemical neuroscience: Clozapine. ACS Chem. Neurosci. 2013, 4, 1018-1025.
[34] Popovic, D.; Nuss, P.; Vieta, E. Revisiting loxapine: A systematic review. Ann. Gen. Psychiatry 2015, 14, 15.
[35] Farah, A. Atypicality of atypical antipsychotics. Prim. Care Companion CNS Disord. 2005, 7, 268-274.
[36] David, S.R.; Taylor, C.C.; Kinon, B.J.; Breier, A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 2000, 22, 1085–1096.
[37] Kerwin, R.W.; Bolonna, A.A. Is clozapine antisuicidal? Expert Rev. Neurother. 2004, 4, 187-190.
[38] Joober, R.; Boksa, P. Clozapine: A distinct, poorly understood and under-used molecule. J. Psychiatry Neurosci. 2010, 35, 147-149.
[39] Schulte, P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann. Pharmacother.
[40] 2006, 40, 683-688.
[41] Patel, N.C.; Dorson, P.G.; Bettinger, T.L. Sudden late onset of clozapine-induced agranulocytosis. Ann. Pharmacother.
[42] 2002, 36, 1012-1015.
[43] Higgins, J.M.; San, C.; Lagnado, G.; Chua, D.; Mihic, T. Incidence and Management of Clozapine-Induced Myocarditis in a Large
[44] Tertiary Hospital. Can. J. Psychiatry 2019, 64, 561-567.
[45] De Fazio, P.; Gaetano, R.; Caroleo, M.; Cerminara, G.; Maida, F.; Bruno, A.; Muscatello, M.R.; Moreno, M.J.J.; Russo, E.; Segura-García, C. Rare and very rare adverse effects of clozapine. Neuropsychiatr. Dis. Treat. 2015, 11, 1995–2003.
[46] Maher, S.; Cunningham, A.; O'Callaghan, N.; Byrne, F.; Mc Donald, C.; McInerney, S.; Hallahan, B. Clozapine-induced hypersali-
[47] vation: An estimate of prevalence, severity and impact on quality of life. Ther. Adv. Psychopharmacol.
[48] 2016, 6, 178-184.
[49] Seeman, P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem. Neurosci. 2014,
[50] Kapur, S.; Zipursky, R.; Jones, C.; Shammi, C.S.; Remington, G.; Seeman, P. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 2000, 57, 553-559.
[51] Siskind, D.; Siskind, V.; Kisely, S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a
[52] Systematic Review and Meta-Analysis. Can. J. Psychiatry 2017, 62, 772-777.
[53] Shad, M.U. Clozapine toxicity: A discussion of pharmacokinetic factors. Asian J. Psychiatry 2008, 1, 47-49.
[54] Prior, T.I.; Baker, G.B. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 2003, 28, 99-112. [PubMed]
[55] Costa-Dookhan, K.A.; Agarwal, S.M.; Chintoh, A.; Tran, V.N.; Stogios, N.; Ebdrup, B.H.; Sockalingam, S.; Rajji, T.K.; Remington, G.J.; Siskind, D.; et al. The clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin. Drug Saf. 2020,
[56] .Kroon, L.A. Drug interactions with smoking. Am. J. Health Pharm. 2007, 64, 1917-1921.
[57] Stieffenhofer, V.; Saglam, H.; Schmidtmann, I.; Silver, H.; Hiemke, C.; Konrad, A. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 2011, 44, 55-59.
[58] Dettling, M.; Sachse, C.; Brockmöller, J.; Schley, J.; Müller-Oerlinghausen, B.; Pickersgill, I.; Rolfs, A.; Schaub, R.T.; Schmider, J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000, 152, 80-86.
[59] Greenwood-Smith, C.; Lubman, D.I.; Castle, D.J. Serum clozapine levels: A review of their clinical utility.J. Psychopharmacol. 2003, 17,234-238.
[60] Olesen, O.V.; Thomsen, K.; Jensen, P.N.; Wulff, C.H.; Rasmussen, N.-A.; Refshammer, C.; Sørensen, J.; Bysted, M.; Christensen, J.; Rosenberg, R. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: A cross-sectional study. Psychopharmacology 1995, 117, 371-378. Biomedicines 2023,
[61] Tiihonen, J.; Wahlbeck, K.; Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia:
[62] A systematic review and
[63] meta-analysis. Schizophr. Res. 2009, 109, 10-14.
[64] Ma, X.; Maimaitirexiati, T.; Zhang, R.; Gui, X.; Zhang, W.; Xu, G.; Hu, G. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis. Int. J. Psychiatry Clin. Pract. 2014, 18, 229–242.
[65] Grover, S.; Nebhinani, N.; Chakrabarti, S.; Avasthi, A.; Kulhara, P. Metabolic syndrome among patients receiving clozapine: A
[66] preliminary estimate. Indian J. Pharmacol. 2011, 43, 591-595.
[67] Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.E.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353, 1209-1223.
[68] Meyer, J.M.; Nasrallah, H.A.; McEvoy, J.P.; Goff, D.C.; Davis, S.M.; Chakos, M.; Patel, J.K.; Keefe, R.S.; Stroup, T.S.; Lieberman, J.A. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005, 80, 9-18.
[69] Lindenmayer, J.P. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Neuropsychiatr. Dis. Treat. 2010, 6, 261–267.
[70] De Silva, V.A.; Suraweera, C.; Ratnatunga, S.S.; Dayabandara, M.; Wanniarachchi, N.; Hanwella, R. Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta- analysis. BMC Psychiatry 2016, 16, 341.
[71] Correll, C.U.; Newcomer, J.W.; Silverman, B.; DiPetrillo, L.; Graham, C.; Jiang, Y.; Du, Y.; Simmons, A.; Hopkinson, C.; McDonnell, D.; et al. Effects of Olanzapine Combined with Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Am. J. Psychiatry 2020, 177, 1168-1178.
[72] Brunette, M.F.; Correll, C.U.; O'Malley, S.S.; McDonnell, D.; DiPetrillo, L.; Jiang, Y.; Simmons, A.; Silverman, B.L.; Citrome, L.; Green, A.I. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial. J. Clin. Psychiatry 2020, 81, 13176.
[73] Hamner, M. The effects of atypical antipsychotics on serum prolactin levels. Ann. Clin. Psychiatry 2002, 14, 163–173.
[74] Sparshatt, A.; Jones, S.; Taylor, D. Quetiapine: Dose-response relationship in schizophrenia. CNS Drugs 2008, 22, 49-68; Discussion 69-72.
[75] Shotbolt, P.; Samuel, M.; David, A. Quetiapine in the treatment of psychosis in Parkinson's disease. Ther. Adv. Neurol. Disord. 2010, 3, 339-350.
[76] Zhong, K.X.; Tariot, P.N.; Mintzer, J.; Minkwitz, M.C.; Devine, N.A. Quetiapine to treat agitation in dementia: A randomized,
[77] double-blind, placebo-controlled study. Curr. Alzheimer Res. 2007, 4, 81-
[78] Patel, R.S.; Bhela, J.; Tahir, M.; Pisati, S.R.; Hossain, S. Pimavanserin in Parkinson's Disease- induced Psychosis: A Literature Review. Cureus 2019, 11, e5257.
[79] Ohman, K.L.; Schultheis, J.M.; Kram, S.J.; Cox, C.E.; Gilstrap, D.L.; Yang, Z.; Kram, B.L. Effectiveness of Quetiapine as a Sedative
[80] Adjunct in Mechanically Ventilated Adults without Delirium. Ann. Pharmacother. 2021, 55, 149-156.
[81] Park, S.; Yi, K.K.; Kim, M.S.; Hong, J.P. Effects of ziprasidone and olanzapine on body composition and metabolic parameters: An
[82] open-label comparative pilot study. Behav. Brain Funct. 2013, 9,27.
[83] Camm, A.J.; Karayal, O.N.; Meltzer, H.; Kolluri, S.; O'Gorman, C.; Miceli, J.; Tensfeldt, T.; Kane, J.M. Ziprasidone and the corrected
[84] QT interval: A comprehensive summary of clinical data. CNS Drugs 2012, 26, 351-365.
[85] Zimbroff, D.L.; Allen, M.H.; Battaglia, J.; Citrome, L.; Fishkind, A.; Francis, A.; Herr, D.L.; Hughes, D.; Martel, M.; Preval, H.; et al. Best clinical practice with ziprasidone IM: Update after 2 years of experience. CNS Spectr. 2005, 10, 1-15.
[86] Miller, D.D. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiatry 2004, 6 (Suppl. 2), 3-7.
[87] Keating, A.M.; Aoun, S.L.; Dean, C.E. Ziprasidone-associated mania: A review and report of 2 additional cases. Clin. Neurophar-macol. 2005, 28, 83-86.
[88] Masand, P.S.; Nemeroff, C.B.; Newcomer, J.W.; Lieberman, J.A.; Schatzberg, A.F.; Weiden, P.J.; Kilts, C.D.; Harvey, P.D.; Daniel, D.G. From clinical research to clinical practice: A 4-year review of ziprasidone. CNS Spectr. 2005, 10 (Suppl. 17), 1-20.
[89] Carnahan, R.M.; Lund, B.C.; Perry, P.J. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001, 21, 717-730.
[90] Green, B. Focus on ziprasidone. Curr. Med. Res. Opin. 2001, 17, 146-150.
[91] Papakostas, G.I.; Fava, M.; Baer, L.; Swee, M.B.; Jaeger, A.; Bobo, W.V.; Shelton, R.C. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results from a Randomized, Double- Blind, Placebo-Controlled Study. Am. J. Psychiatry 2015, 172, 1251-1258.
[92] Shad, M.; Preskorn, S.; Miceli, J.; Wilner, K. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clin. Pharmacol. Ther. 1999, 65, 171.
[93] Spina, E.; de Leon, J. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin. Pharmacol. Toxicol. 2007, 100, 4-22.
[94] Citrome, L. Using oral ziprasidone effectively: The food effect and dose-response. Adv. Ther. 2009, 26, 739-748. 11, 130
[95] Urichuk, L.; Prior, T.I.; Dursun, S.; Baker, G. Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008, 9, 410-418.
[96] Amatniek, J.; Canuso, C.M.; Deutsch, S.I.; Henderson, D.C.; Mao, L.; Mikesell, C.; Rodriguez, S.; Sheehan, J.; Alphs, L. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease. Clin. Schizophr. Relat. Psychoses 2014, 8, 8-20.
[97] Chan, H.W.; Huang, C.Y.; Yen, Y.C. Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: A 1-year retrospective cohort study. BMC Psychiatry 2021, 21, 507.
[98] Caccia, S.; Pasina, L.; Nobili, A. New atypical antipsychotics for schizophrenia: Iloperidone. Drug Des. Dev. Ther. 2010, 4, 33-48.
[99] Citrome, L. Iloperidone: A clinical overview. J. Clin. Psychiatry 2011, 72 (Suppl. 1), 19-23.
[100] Shuman, M.D.; McGrane, I.R. Rationale for iloperidone in the treatment of posttraumatic stress disorder. Innov. Clin. Neurosci. 2014, 11, 23-25.
Joshi, S.V.; Patel, E.P.; Vyas, B.A.; Lodha, S.R.; Kalyankar, G.G. Repurposing of Iloperidone:
[101] Antihypertensive and ocular
[102] hypotensive activity in animals. Eur. J. Pharm. Sci. 2020, 143, 105173. Llerena, A.; Berecz, R.; Dorado, P.; de la Rubia, A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma
[103] concentrations. J. Psychopharmacol. 2004, 18, 189- 193.
[104] 88.Pratts, M.; Citrome, L.; Grant, W.; Leso, L.; Opler, L.A. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr. Scand. 2014, 130, 61- 68.
[105] Citrome, L. Iloperidone, asenapine, and lurasidone: A brief overview of 3 new second-generation antipsychotics. Postgrad. Med. 2011, 123, 153–162.
[106] McIntyre, R.S.; Wong, R. Asenapine: A synthesis of efficacy data in bipolar mania and schizophrenia. Clin. Schizophr. Relat.
[107] Psychoses 2012, 5, 217-220.
[108] Tarazi, F.I.; Neill, J.C. The preclinical profile of asenapine: Clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin. Drug Discov. 2013, 8, 93-103.
[109] Ballaz, S.J.; Akil, H.; Watson, S.J. The 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007, 149, 192-202.
[110] Shayegan, D.K.; Stahl, S.M. Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004, 9 (Suppl. 11), 6-14.
[111] Kroeze, W.K.; Hufeisen, S.J.; Popadak, B.A.; Renock, S.M.; Steinberg, S.; Ernsberger, P.; Jayathilake, K.; Meltzer, H.Y.; Roth, B.L. H1- histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28, 519-526.
[112] Potkin, S.G.; Keator, D.B.; Kesler-West, M.L.; Nguyen, D.D.; van Erp, T.G.M.; Mukherjee, J.; Shah, N.; Preda, A. D2 re- ceptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014, 19, 176-181.
[113] Meyer, J.M.; Loebel, A.D.; Schweizer, E. Lurasidone: A new drug in development for schizophrenia. Expert Opin. Investig. Drugsm2009, 18, 1715-1726.
[114] Grunder, G.; Carlsson, A.; Wong, D.F. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch. Gen. Psychiatry 2003, 60, 974-977.
[115] Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J. Clin. Psychiatry 2001, 62, 923–924.
[116] Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J. Clin. Psychiatry 2001, 62, 841-842.
[117] Nasrallah, H.A.; Mulvihill, T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann. Clin. Psychiatry 2001, 13, 215-227.
[118] Kim, D.D.; Barr, A.M.; Lian, L.; Yuen, J.W.Y.; Fredrikson, D.; Honer, W.G.; Thornton, A.E.; Procyshyn,
[119] R.M. Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early course of schizophrenia: A systematic review and meta-analysis. Npj Schizophr. 2021, 7, 29.
[120] Singh, T. Aripiprazole-induced weight gain. Psychiatry 2005, 2, 19.
[121] Kelly, D.L.; Powell, M.M.; Wehring, H.J.; Sayer, M.A.; Kearns, A.M.; Hackman, A.L.; Buchanan, R.; Nichols, R.B.; McEvoy, J.P.; Adams, H.A.; et al. Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women with Psychosis: Results from the DAAMSEL Clinical Trial. J. Clin. Psychopharmacol. 2018, 38, 317-326.
[122] Yeager, A.; Shad, M.U. Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia: A Retrospective Case Series. Prim. Care Companion CNS Disord. 2020, 22, 26648.
[123] Nguyen, C.T.; Rosen, J.A.; Bota, R.G. Aripiprazole partial agonism at 5-HT2C: A comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities. Prim. Care Companion CNS Disord. 2012, 14, 26654.
[124] Citrome, L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr. Dis. Treat. 2006, 2, 427-443.
[125] Fryefield, K.; Shad, M.U. Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable? Schizophr.Res. 2019, 204, 417-418.
[126] Potkin, S.G.; Preda, A. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opin. Pharmacother. 2016, 17, 395-407.
[127] Cruz, M.P. Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia. Pharm. Ther. 2016, 41, 556-559.
[128] Ehret, M.J.; Davis, E.; Luttrell, S.E.; Clark, C. Aripiprazole Lauroxil NanoCrystal® Dispersion Technology (Aristada Initio®). Clin. Schizophr. Relat. Psychoses 2018, 12, 92-96.
[129] Di Lorenzo, R.; Ferri, P.; Cameli, M.; Rovesti, S.; Piemonte, C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: Retrospective study in a real-world clinical setting. Neuropsychiatr. Dis. Treat. 2019, 15, 183-198.
[130] Mason, K.; Barnett, J.; Pappa, S. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. Ther. Adv. Psychopharmacol. 2021, 11, 20451253211029490.
[131] Kishimoto, T.; Hagi, K.; Nitta, M.; Leucht, S.; Olfson, M.; Kane, J.M.; Correll, C.U. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients with Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr. Bull. 2018, 44, 603-619.
[132] Tiihonen, J.; Mittendorfer-Rutz, E.; Majak, M.; Mehtälä, J.; Hoti, F.; Jedenius, E.; Enkusson, D.; Leval, A.; Sermon, J.; Tanskanen, A.; et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients with Schizophrenia. JAMA Psychiatry 2017, 74, 686-693.
[133] Garnock-Jones, K.P. Cariprazine: A Review in Schizophrenia. CNS Drugs 2017, 31, 513-525.
[134] Campbell, R.H.; Diduch, M.; Gardner, K.N.; Thomas, C. Review of cariprazine in management of psychiatric illness. Ment. Health Clin. 2017,
[135] McCormack, P.L. Cariprazine: First Global Approval. Drugs 2015,
[136] Durgam, S.; Earley, W.; Guo, H.; Li, D.; Németh, G.; Laszlovszky, I.; Fava, M.; Montgomery, S.A. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J. Clin. Psychiatry 2016, 77, 371-378.
[137] Stahl, S.M. Mechanism of action of cariprazine. CNS Spectr. 2016, 21, 123-127.
[138] Thase, M.E.; Youakim, J.M.; Skuban, A.; Hobart, M.; Zhang, P.; McQuade, R.D.; Nyilas, M.; Carson, W.H.; Sanchez, R.; Eriksson, H. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: A phase 3, randomized, double-blind study. J. Clin. Psychiatry 2015, 76, 1232-1240.
[139] Maeda, K.; Sugino, H.; Akazawa, H.; Amada, N.; Shimada, J.; Futamura, T.; Yamashita, H.; Ito, N.;
[140] McQuade, R.D.; Mørk, A.; et al. Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin- dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350, 589-604.
[141] Citrome, L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 2015, 69, 978-997. [PubMed]
[142] Stahl, S.M. Mechanism of action of brexpiprazole: Comparison with aripiprazole. CNS Spectr. 2016, 21, 1-6.
[143] Correll, C.U.; Skuban, A.; Ouyang, J.; Hobart, M.; Pfister, S.; McQuade, R.D.; Nyilas, M.; Carson, W.H.; Sanchez, R.; Eriksson,
[144] H. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. Am. J. Psychiatry 2015, 172, 870-880.
[145] Ward, K.; Citrome, L. Brexpiprazole for the maintenance treatment of adults with schizophrenia: An evidence-based review and place in therapy. Neuropsychiatr. Dis. Treat. 2019, 15, 247-257.
[146] Syed, A.B.; Brasic, J.R. The role of lumateperone in the treatment of schizophrenia. Ther. Adv. Psychopharmacol. 2021, 11,
[147] 20451253211034019.
[148] Snyder, G.L.; Vanover, K.E.; Davis, R.E.; Li, P.; Fienberg, A.; Mates, S. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Adv. Pharmacol. 2021, 90, 253–276.
[149] Correll, C.U.; Davis, R.E.; Weingart, M.; Saillard, J.; O'Gorman, C.; Kane, J.M.; Lieberman, J.A.; Tamminga, C.A.; Mates, S.; Vanover, K.E. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry 2020, 77, 349-358.
[150] Vanover, K.E.; Davis, R.E.; Zhou, Y.; Ye, W.; Brašić, J.R.; Gapasin, L.; Saillard, J.; Weingart, M.; Litman, R.E.; Mates, S.; et al. Dopamine D(2) receptor occupancy of lumateperone (ITI-007): A Positron Emission
[151] Tomography Study in patients with schizophrenia. Neuropsychopharmacology 2019, 44, 598–605.
[152] Kane, J.M.; Durgam, S.; Satlin, A.; Vanover, K.E.; Chen, R.; Davis, R.; Mates, S. Safety and tolerability of lumateperone for the treatment of schizophrenia: A pooled analysis of late-phase placebo- and active-controlled clinical trials. Int. Clin. Psychopharmacol. 2021, 36, 244-250.
[153] Correll, C.U.; Vanover, K.E.; Davis, R.E.; Chen, R.; Satlin, A.; Mates, S. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
